Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma

Clinical Cancer Research

Volumn 15, Issue 6, 2009, Pages 1931-1939

  Nevaia, Wendy K ^a,b   Vachon, Celine M ^a   Leontovich, Alexey A ^a   Scott, Christopher G ^a   Thompson, Michael A ^a,b   Markovic, Svetomir N ^a,b,c  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; RNA; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL FUNCTION; CHRONIC INFLAMMATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HOMEOSTASIS; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MICROARRAY ANALYSIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REPOLARIZATION; RNA ISOLATION; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TH2 CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 63549104097     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1980     Document Type: Article

References (49)

1. Finkelstein SE, Heimann DM, Klebanoff CA, et al. Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J Leukoc Biol 2004;76:333-7.
2. RikerAI, Jove R, Daud AI. Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front Biosci 2006;11:1 -14.
3. + T cells in patients with melanoma. J Immunol 2005;175: 6169-76.
4. Vaishampayan U, Abrams J, Darrah D, Jones V, Mitchell MS. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon a. Clin Cancer Res 2002;8:3696-701.
5. Osanto S, Schiphorst PP, Weijl NI, et al.Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum GeneTher 2000;11:739-50.
6. Palucka AK, Dhodapkar MV, Paczesny S, et al. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J Immunother 2003;26:432-9.
7. + progenitors and activated with type I interferon. J Immunother 2005;28: 505-16. 8. Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006;213:131 -45.
8. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (NY) 2002;298:850-4.
9. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified Tcells for ovarian cancer. Clin Cancer Res 2006;12:6106-15.
10. 11.Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-77.
11. Rasku MA, Clem AL, Telang S, et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med2008;6:12.
12. + T cells against NY-ESO-1. N Engl J Med 2008;358: 2698-703.
13. Terheyden P, Schrama D, Pedersen LO, et al. Longitudinal analysis of MART-1/HLA-A2-reactiveTcells over the course of melanoma progression. Scand J Immunol 2003;58:566-71.
14. Bunt SK,Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res2007;67:10019-26.
15. Tatsumi T, Kierstead LS, Ranieri E, et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4( + ) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002;196:619-28.
16. Bose A, ChakrabortyT, Chakraborty K, Pal S, Baral R. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 2008;8:10.
17. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.J Immunol 2001;166:678-89.
18. FrickeI, Mirza N, Dupont J, et al. Vascularendo-thelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 2007;13:4840-8.
19. Markovic SN, Nevala WK, Uhl CB, Celis E, McKean DJ. Areproducible method for the enumeration of functional (cytokine producing) versusnon-functional peptide-specific cytotoxicT lymphocytes in human peripheral blood.Clin ExpImmunol 2006;145:438-47.
20. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics2003;19:185-93.
21. + T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996;42:1 -8.
22. Kobayashi M, Kobayashi H, Pollard RB, Suzuki F. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 1998;160:5869-73.
23. Sester U, Presser D, Dirks J, Gartner BC, Kohler H, Sester M. PD-1 expression and IL-2 loss of cytomega-lovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 2008; 7: 1486-97.
24. Wong RM, Scotland RR, Lau RL, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 2007;19:1223-34.
25. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors1and 2 in melanoma patients. Melanoma Res 2006;16: 405-11.
26. Gabrilovich DI,ChenHL,GirgisKR,etal. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med1996;2:1096-103.
27. Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhan-cesTH2-mediated sensitization and inflammation in thelung. Nat Med 2004;10:1095-103.
28. Mahmoud FA, Rivera NI. Therole of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002;4:250-5.
29. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
30. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl JMed1990;323:1228-33.
31. Medrano EE, Farooqui JZ, Boissy RE, Boissy Y L, Akadiri B, Nordlund JJ. Chronic growth stimulation of human adult melanocytes by inflammatory mediators in vitro: implications for nevus formation and initial steps in melanocyte oncogenesis. Proc Natl Acad Sci U SA1993;90:1790-4.
32. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211 -7.
33. +Tregulatorycells: crosstalk between two professionals in immunity versus tolerance. Front Bio sci 2006; 11: 1360-70.
34. de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 2006;13:118-37.
35. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. CritRevOncol Hematol 2008;66:1 -9.
36. Riccobon A, Gunelli R, Ridolfi R, et al. Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes. Cancer Invest 2004;22:871 -7.
37. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
38. Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 2008;222:101 -16.
39. + regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008;111:5359-70.
40. + T cells in a Th2 dominant microenvironment. J Invest Dermatol 2007;127:2391 -8.
41. + Treg clones obtained from peripheral blood of patientswith cancer. Int J Cancer 2007;121:2473-83.
42. Sarih M, Bouchrit N, BenslimaneA. Different cytokine profiles of peripheral blood mononuclear cells from patients with persistent and self-limited hepatitis C virusinfection. Immunol Lett 2000;74:117-20.
43. Sindhu S, Toma E, Cordeiro P, Ahmad R, Morisset R, Menezes J. Relationship of in vivo and ex vivo levels of TH1 and TH2 cytokines with viremia in HAART patients with and without opportunistic infections. J Med Virol 2006;78:431 -9.
44. Berin MC, Dwinell MB, Eckmann L, Kagnoff MF. Production of MDC/CCL22 by human intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2001;280:G1217-26.
45. Mellor AL, Munn DH. Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. Annu Rev Immunol 2000;18:367-91.
46. Lin YL, Liang YC, Chiang BL. Placental growth factor down-regulates type 1 T helper immune response by modulating the function of dendritic cells. J Leukoc Biol 2007;82:1473-80.
47. Brychtova S, Bezdekova M, Brychta T, Tichy M. The role of vascular endothelial growth factors and their receptors in malignant melanomas. Neoplasma 2008;55:273-9.
48. Powell DJ, Jr., Dudley ME, Hogan KA,Wunderlich JR, Rosenberg SA. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lym-phodepletion. J Immunol 2006;177:6527-39.
49. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002;99:16168-73.